39971-36-3

Usage

Uses

Used in Flavoring and Fragrance Industry:
Methyl 5-acetyl-2-methoxybenzoate is used as a flavoring agent and fragrance ingredient for its distinctive sweet, floral, and fruity aroma. It is incorporated into the production of perfumes, soaps, and other scented products to enhance their appeal.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, methyl 5-acetyl-2-methoxybenzoate is utilized in the synthesis of various medications, contributing to the development of new therapeutic agents.
Used as a Food Additive:
Methyl 5-acetyl-2-methoxybenzoate is used as a food additive to enhance the flavor of various food products, providing a pleasant taste and aroma while maintaining its reputation for low toxicity and stability.

InChI:InChI=1/C11H12O4/c1-7(12)8-4-5-10(14-2)9(6-8)11(13)15-3/h4-6H,1-3H3

Upstream product

• 16475-90-4 estere metilico dell'acido 5-acetilsalicilico 
• 74-88-4 methyl iodide 
• 13110-96-8 5-acetylsalicylic acid 
• 67-56-1 methanol 
• 13235-60-4 4-methoxy-1,3-benzenedicarbonyl dichloride 
• 75-16-1 methylmagnesium bromide 
• 186581-53-3 diazomethane 
• 68535-61-5 3-carboxy-4-methoxy-acetophenone 

Downstream Products

• 68535-61-5 3-carboxy-4-methoxy-acetophenone 
• 1373428-00-2 methyl 5-(2-(4-(2,3,4-trimethoxybenzyl)piperazin-1-yl)acetyl)-2-(methoxy)benzoate 
• 1373428-09-1 5-(2-(4-(2,3,4-trimethoxybenzyl)piperazin-1-yl)acetyl)-2-(methoxy)benzoic acid 
• 478163-41-6 5-acetyl-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide 
• 1201798-99-3 methyl 5-[(2E)-3-(dimethylamino)prop-2-enoyl]-2-methoxybenzoate 
• 439145-86-5 5-isobutyryl-2-methoxy-benzoic acid methyl ester 
• 802604-14-4 5-[2-(Benzyl-tert-butyl-amino)-acetyl]-2-methoxy-benzoic acid methyl ester 
• 802884-57-7 2-(Benzyl-tert-butyl-amino)-1-(3-hydroxymethyl-4-methoxy-phenyl)-ethanol 
• 18910-69-5 2-tert-Butylamino-1-(3-hydroxymethyl-4-methoxy-phenyl)-ethanol 
• 24085-34-5 5-bromoacetyl-2-methoxy-benzoic acid methyl ester 

Relevant academic research and scientific papers

Diaryl-substituted 1, 1-ethylene compounds and preparation method and application thereof

The invention discloses diaryl-substituted 1, 1-ethylene compounds shown as general formulas I, II, III and IV, and a preparation method and application thereof, and the compounds can be used for preparing medicines related to tumor treatment, tubulin activity inhibition and HDAC activity inhibition.

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Synthesis and bioactivity of substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors

A novel series of substituted benzoylguanidine derivatives were designed and synthesized in order to evaluate their NHE1 inhibitory activity. Most of them were found to inhibit NHE1-mediated platelet swelling in a concentration-dependent manner, and eight compounds showed more potent NHE1 inhibitory activity than Cariporide. Compound 6f with an IC50 value of 1.08 × 10-10 molmiddot;L-1, was 39 times more potent than lead compound CPU-X-050420 in vitro tests. A novel series of 5-(2-(4-(2,3,4-trimethoxybenzyl)piperazin-1-yl)acetyl)benzoylguanidine derivatives 6a-6i have been synthesized and screened for their NHE1 inhibitory activity. Copyright

COMPOSITION AND PROCESS - 356

There is provided a process for the preparation of a compound of Formula 1, the use of said process in the preparation of a compound of Formula 5 or a phosphate, sulphate, hydrogensulphate, malate, citrate, tartrate or fumarate salt thereof, and the use of the fumarate salt in a composition for use in therapy.

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

THERAPEUTIC AGENT FOR CANCER

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

IMMUNITY-RELATED PROTEIN KINASE INHIBITORS

[From equivalent EP1510210A1] A medicament having an inhibitory activity against IKK-Aβ and/or MEKK-1 or other protein kinases structurally similar thereto, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.

INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT

A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.